FTSE MIB
34.525,03 -78,58 (-0,23%) Dow Jones
39.872,99 +66,22 (+0,17%) Nasdaq
16.832,62 +37,75 (+0,22%) Nikkei 225
38.617,10 -329,83 (-0,85%) Petrolio
77,74 -0,92 (-1,17%) Bitcoin EUR
64.443,16 -1.120,86 (-1,71%)
NeurAxis, Inc. (NRXS)
Dopo ore:
| Chiusura precedente | 2,9700 |
| Aperto | 3,0000 |
| Denaro | 0,0000 x 1000 |
| Domanda | 0,0000 x 800 |
| Min-Max giorno | 2,8200 - 3,0600 |
| Intervallo di 52 settimane | 1,8000 - 6,9300 |
| Volume | |
| Media Volume | 8.732 |
| Capitalizzazione | 20,114M |
| Beta (mensile su 5 anni) | N/D |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -2,2400 |
| Prossima data utili | N/D |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireNeurAxis Announces Results of Comparative Study of IB-Stim™ and Standard Medical Therapy in Adolescents with Functional Abdominal Pain Disorders
CARMEL, Ind., Sept. 26, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today announced the results of a retrospective comparative study of adolescent patients with functional abdominal pain disorders (FAPD) treated with IB-Stim™ therapy or standard of care medications, amitriptyline (tricyclic antidepressant
- GlobeNewswire
NeurAxis Reports Second Quarter 2023 Financial Results
CARMEL, Ind., Sept. 21, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today reported financial results for the second quarter ended June 30, 2023. Recent Highlights: Announced a poster presentation titled, “Percutaneous Electrical Nerve Field Stimulation Saves Cost to Parents and Insurers of Adolescents with
- GlobeNewswire
NeurAxis to Present at the Gilmartin Group Emerging Growth Showcase
CARMEL, Ind., Sept. 13, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS), (“NeurAxis,” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today announced that President and Chief Executive Officer Brian Carrico and Chief Medical Officer Dr. Adrian Miranda, will present at the upcoming Gilmartin Group Emerging Growth Showcase on Thursday, September 21, 2023, at 9:00 am ET.
